Investment Analyst
Benzion joined Arkin Capital in 2025 as an investment analyst, applying his scientific training to identify investment opportunities and generate insights across therapeutics, disease biology, and financial and strategic aspects.
Prior to Arkin, he spent two years at Sphera Funds as a biotech equity analyst, focusing on company modeling and fundamentals-driven due diligence across clinical-stage healthcare companies.
Benzion holds a PhD in Pharmaceutical Sciences and an MBA, both from the Hebrew University of Jerusalem.
Let’s get in touch!
